{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:52:31Z","timestamp":1791643951502,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment and is highly effective with low-dose intermittent administration. MTX is occasionally used in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen (APAP)\/paracetamol for pain or inflammation control. With MTX treatment, the side effects, such as hepatotoxicity, renal failure, and myelosuppression should be considered. These are also seen with analgesics treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used a large spontaneously reported adverse event database (FAERS [JAPIC AERS]) to analyze whether the reporting of adverse events increased upon MTX and analgesic therapy in patients with RA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After identifying RA cases, the crude reporting odds ratios (cRORs) for hepatotoxicity, renal failure, and thrombocytopenia associated with the use of MTX, APAP, or NSAIDs were calculated by disproportionality analysis, which revealed significantly higher cRORs for these events. No analgesics showed consistent positive signals for drug-drug interaction (DDI) with concomitant low-dose MTX analyzed using four algorithms for DDI interaction (the \u2126 shrinkage measure, additive or multiplicative, and combination risk ratio models). However, in renal failure and thrombocytopenia, loxoprofen (\u2126<jats:sub>025<\/jats:sub>\u2009=\u20090.08) and piroxicam (\u2126<jats:sub>025<\/jats:sub>\u2009=\u20090.46), and ibuprofen (\u2126<jats:sub>025<\/jats:sub>\u2009=\u20090.74) and ketorolac (\u2126<jats:sub>025<\/jats:sub>\u2009=\u20093.52), respectively, showed positive signals in the \u2126 shrinkage measure model, and no consistency was found among adverse events or NSAIDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Studies using spontaneous reporting systems have limitations such as reporting bias or lack of patient background; however, the results of our comprehensive analysis support the results of previous clinical or epidemiological studies. This study also demonstrated the usefulness of FAERS for DDI assessment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-024-00738-6","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:03:06Z","timestamp":1706774586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Drug-drug interaction assessment based on a large-scale spontaneous reporting system for hepato- and renal-toxicity, and thrombocytopenia with concomitant low-dose methotrexate and analgesics use"],"prefix":"10.1186","volume":"25","author":[{"given":"Takeshi","family":"Honma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Masuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"738_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502\u201316.","journal-title":"Eur J Med Chem"},{"key":"738_CR2","doi-asserted-by":"crossref","unstructured":"Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;:CD000951.","DOI":"10.1002\/14651858.CD000951.pub2"},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"18715","DOI":"10.1038\/s41598-020-75655-9","volume":"10","author":"K Hayashi","year":"2020","unstructured":"Hayashi K, Sada K-E, Asano Y, Asano SH, Yamamura Y, Ohashi K, et al. Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Sci Rep. 2020;10:18715.","journal-title":"Sci Rep"},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms20205023","volume":"20","author":"Y Bedoui","year":"2019","unstructured":"Bedoui Y, Guillot X, S\u00e9lambarom J, Guiraud P, Giry C, Jaffar-Bandjee MC, et al. Methotrexate an Old Drug with New tricks. Int J Mol Sci. 2019;20:5023.","journal-title":"Int J Mol Sci"},{"key":"738_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1179\/acb.2006.028","volume":"61","author":"O Boey","year":"2006","unstructured":"Boey O, Van Hooland S, Woestenburg A, Van der Niepen P, Verbeelen D. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg. 2006;61:166\u20139.","journal-title":"Acta Clin Belg"},{"key":"738_CR6","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00296-011-2041-5","volume":"31","author":"H Al-Hasani","year":"2011","unstructured":"Al-Hasani H, Roussou E. Methotrexate for rheumatoid arthritis patients who are on hemodialysis. Rheumatol Int. 2011;31:1545\u20137.","journal-title":"Rheumatol Int"},{"issue":"Suppl 3 Suppl 3","key":"738_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/ar4174","volume":"15","author":"LJ Crofford","year":"2013","unstructured":"Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl 3 Suppl 3):2.","journal-title":"Arthritis Res Ther"},{"key":"738_CR8","first-page":"CD003789","volume":"2004","author":"T Wienecke","year":"2004","unstructured":"Wienecke T, G\u00f8tzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2004;2004:CD003789.","journal-title":"Cochrane Database Syst Rev"},{"key":"738_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/jpet.102.034330","volume":"302","author":"M Takeda","year":"2002","unstructured":"Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther. 2002;302:666\u201371.","journal-title":"J Pharmacol Exp Ther"},{"key":"738_CR10","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00296-020-04526-3","volume":"40","author":"S Pflugbeil","year":"2020","unstructured":"Pflugbeil S, B\u00f6ckl K, Pongratz R, Leitner M, Graninger W, Ortner A. Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatol Int. 2020;40:511\u201321.","journal-title":"Rheumatol Int"},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-197803010-00001","volume":"3","author":"DD Shen","year":"1978","unstructured":"Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978;3:1\u201313.","journal-title":"Clin Pharmacokinet"},{"key":"738_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.106.110379","volume":"320","author":"AAK El-Sheikh","year":"2007","unstructured":"El-Sheikh AAK, van den Heuvel JJMW, Koenderink JB, Russel FGM. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2\/ABCC2- and MRP4\/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007;320:229\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/978-3-642-69132-4_56","volume":"7","author":"MJ Dunn","year":"1984","unstructured":"Dunn MJ, Scharschmidt L, Zambraski E. Mechanisms of the nephrotoxicity of non-steroidal anti-inflammatory drugs. Arch Toxicol Suppl Arch Toxikol Suppl. 1984;7:328\u201337.","journal-title":"Arch Toxicol Suppl Arch Toxikol Suppl"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1248\/bpb.b16-00970","volume":"40","author":"M Iwaki","year":"2017","unstructured":"Iwaki M, Shimada H, Irino Y, Take M, Egashira S. Inhibition of Methotrexate Uptake via Organic Anion transporters OAT1 and OAT3 by Glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull. 2017;40:926\u201331.","journal-title":"Biol Pharm Bull"},{"key":"738_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00278469","volume":"42","author":"TS Tracy","year":"1992","unstructured":"Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol. 1992;42:121\u20135.","journal-title":"Eur J Clin Pharmacol"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/pds.4555","volume":"27","author":"H Svanstr\u00f6m","year":"2018","unstructured":"Svanstr\u00f6m H, Lund M, Melbye M, Pasternak B. Concomitant use of low-dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2018;27:885\u201393.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"738_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3899\/jrheum.120345","volume":"90","author":"AN Colebatch","year":"2012","unstructured":"Colebatch AN, Marks JL, van der Heijde DM, Edwards CJ. Safety of nonsteroidal antiinflammatory drugs and\/or Paracetamol in people receiving methotrexate for inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012;90:62\u201373.","journal-title":"J Rheumatol Suppl"},{"key":"738_CR18","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/hep.1840220312","volume":"22","author":"HJ Zimmerman","year":"1995","unstructured":"Zimmerman HJ, Maddrey WC. Acetaminophen (Paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatol Baltim Md. 1995;22:767\u201373.","journal-title":"Hepatol Baltim Md"},{"key":"738_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.clinthera.2006.05.002","volume":"28","author":"O Moling","year":"2006","unstructured":"Moling O, Cairon E, Rimenti G, Rizza F, Prister\u00e1 R, Mian P. Severe hepatotoxicity after therapeutic doses of acetaminophen. Clin Ther. 2006;28:755\u201360.","journal-title":"Clin Ther"},{"key":"738_CR20","doi-asserted-by":"publisher","first-page":"c6764","DOI":"10.1136\/bmj.c6764","volume":"341","author":"LC Claridge","year":"2010","unstructured":"Claridge LC, Eksteen B, Smith A, Shah T, Holt AP. Acute liver failure after administration of Paracetamol at the maximum recommended daily dose in adults. BMJ. 2010;341:c6764.","journal-title":"BMJ"},{"key":"738_CR21","first-page":"131","volume":"4","author":"E Yoon","year":"2016","unstructured":"Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update. J Clin Transl Hepatol. 2016;4:131\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"738_CR22","doi-asserted-by":"crossref","unstructured":"Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and Paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011;:CD008872.","DOI":"10.1002\/14651858.CD008872.pub2"},{"key":"738_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796\u2013803.","journal-title":"Int J Med Sci"},{"key":"738_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"738_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1331\/JAPhA.2013.12218","volume":"53","author":"PK Gandhi","year":"2013","unstructured":"Gandhi PK, Gentry WM, Bottorff MB. Dabigatran-Dronedarone interaction in a spontaneous reporting system. J Am Pharm Assoc JAPhA. 2013;53:414\u20139.","journal-title":"J Am Pharm Assoc JAPhA"},{"key":"738_CR26","doi-asserted-by":"publisher","first-page":"206ra140","DOI":"10.1126\/scitranslmed.3006548","volume":"5","author":"S Zhao","year":"2013","unstructured":"Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, et al. Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013;5:206ra140.","journal-title":"Sci Transl Med"},{"key":"738_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/amiajnl-2013-001612","volume":"21","author":"SV Iyer","year":"2014","unstructured":"Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc JAMIA. 2014;21:353\u201362.","journal-title":"J Am Med Inform Assoc JAMIA"},{"key":"738_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","volume":"47","author":"EP Van Puijenbroek","year":"1999","unstructured":"Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol. 1999;47:689\u201393.","journal-title":"Br J Clin Pharmacol"},{"key":"738_CR29","doi-asserted-by":"publisher","first-page":"1030832","DOI":"10.3389\/fphar.2023.1030832","volume":"14","author":"K Onda","year":"2023","unstructured":"Onda K, Honma T, Masuyama K. Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: an assessment using the FDA adverse event reporting system. Front Pharmacol. 2023;14:1030832.","journal-title":"Front Pharmacol"},{"key":"738_CR30","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","volume":"27","author":"GN Nor\u00e9n","year":"2008","unstructured":"Nor\u00e9n GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27:3057\u201370.","journal-title":"Stat Med"},{"key":"738_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","volume":"64","author":"BT Thakrar","year":"2007","unstructured":"Thakrar BT, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64:489\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"738_CR32","first-page":"39","volume":"19","author":"Y Susuta","year":"2014","unstructured":"Susuta Y, Takahashi Y. Safety risk evaluation methodology in detecting the medicine concomitant use risk which might cause critical drug rash. Jpn J Pharmacoepidemiol. 2014;19:39\u201349.","journal-title":"Jpn J Pharmacoepidemiol"},{"key":"738_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H. Comparison of Signal Detection Algorithms based on frequency statistical model for drug-drug Interaction using spontaneous Reporting systems. Pharm Res. 2020;37:86.","journal-title":"Pharm Res"},{"key":"738_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40264-022-01166-3","volume":"45","author":"W Alkabbani","year":"2022","unstructured":"Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble J-M. Drug-Drug Interaction of the Sodium glucose co-transporter 2 inhibitors with statins and Myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45:287\u201395.","journal-title":"Drug Saf"},{"key":"738_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-022-01191-2","volume":"45","author":"Y Noguchi","year":"2022","unstructured":"Noguchi Y. Comment on: Drug-Drug Interaction of the Sodium glucose co-transporter 2 inhibitors with statins and Myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45:809\u201311.","journal-title":"Drug Saf"},{"key":"738_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF02230334","volume":"15","author":"H Franck","year":"1996","unstructured":"Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol. 1996;15:163\u20137.","journal-title":"Clin Rheumatol"},{"key":"738_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","volume":"36","author":"F Salvo","year":"2013","unstructured":"Salvo F, Leborgne F, Thiessard F, Moore N, B\u00e9gaud B, Pariente A. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf. 2013;36:565\u201372.","journal-title":"Drug Saf"},{"key":"738_CR38","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3389\/fphar.2019.01319","volume":"10","author":"Y Noguchi","year":"2019","unstructured":"Noguchi Y, Tachi T, Teramachi H. Review of statistical methodologies for detecting drug-drug interactions using spontaneous Reporting systems. Front Pharmacol. 2019;10:1319.","journal-title":"Front Pharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00738-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00738-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T08:04:52Z","timestamp":1706774692000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00738-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00738-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}